Search

everythinglearnresearchcommunity

for

Search:↓

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

EGFR inhibitors can cause yellowish skin eruptions.

Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.

Panitumumab can cause excessive ear hair growth.

Blocking EGFR in skin cells doesn't majorly increase inflammation markers.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

Vitamin B supplements may reverse grey hair.

EGFR inhibitors can cause unusual localized hair growth.

Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

Lysocellin helps stop cell damage from etoposide and may prevent hair loss.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Reducing gefitinib dosage improved hair loss, but scarring remained.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

Ritlecitinib can help about 14,000 people with severe hair loss.

Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.

Ritlecitinib is safe and may effectively treat alopecia areata.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Gefitinib therapy can cause unusual hair growth on the nose.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

A woman's hair turned white after taking a cancer drug called dasatinib.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.